Gary, given your interest in biotechs, wondered if you noticed Faber interviewing the CEO of REPL this am. Cancer stock, submitted to and rejected by the FDA twice, CEO advised they had a recent meeting with the FDA, received positive input, at least positive enough that he plans to resubmit a 3rd time. Almost doubled today, but still only an $8 stock. Not for me, one speculative is enough, but maybe of interest to you.
Market Data 
Markets 
